Harnessing innate immunity in cancer therapies: the example of Natural Killer Cell Engagers
Vivier, et al.
Tetrafunctional NKCE-IL2v thus constitutes a synthetic technological platform combining the induction of NK cell proliferation and effector functions without toxicity, supporting its clinical development for next-generation cancer immunotherapies.
Penpulimab, an IgG1 anti-PD-1 antibody with Fc-engineering to eliminate effector functions and with unique epitope and binding properties
Li, et al.
Penpulimab, a PD-1 antibody with IgG1 isotype and Fc engineering, exhibits no Fc receptor mediated effector functions including ADCC, ADCP, and ADCR, and has robust T cell stimulating activity via blocking of PD-1.
Patient-derived micro-organospheres (MOS) recapitulate tumor microenvironment and heterogeneity for precision oncology
Din, et al.
Micro-organospheres are a rapid and scalable platform to preserve patient tumor microenvironment and heterogeneity. This platform will be useful for precision oncology, drug discovery, and immunotherapy development.
Multi-omic characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation
Á. Quintanal-Villalonga, et al.
Our findings provide the first comprehensive molecular characterization of LUSC transdifferentiation, suggesting putative drivers and promising therapeutic targets to constrain or prevent lineage plasticity in this setting.